Anthony Lapointe - ImmunoCellular Therapeutics Independent Director
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
Director
Mr. Gregg A. Lapointe, CPA., is Independent Director of ImmunoCellular Therapeutics, Ltd. Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company. He previously served as Chief Operating Officer and then as Chief Executive Officer of SigmaTau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. whollyowned subsidiary of SigmaTau Finanziaria S.p.A. Lapointe is a Certified Public Accountant . He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and a MBA degree from Duke University . Mr. Lapointe also serves on the Boards of Directors of SciClone Pharmaceuticals, Inc., Soligenix, Inc., and Raptor Pharmaceuticals Corporationration since 2015.
| Age | 58 |
| Tenure | 9 years |
| Phone | 201 351 0605 |
| Web | https://www.eompharma.com |
ImmunoCellular Therapeutics Management Efficiency
The company has return on total asset (ROA) of (4.4045) % which means that it has lost $4.4045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (23.12) %, meaning that it created substantial loss on money invested by shareholders. ImmunoCellular Therapeutics' management efficiency ratios could be used to measure how well ImmunoCellular Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.78 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. ImmunoCellular Therapeutics has a current ratio of 1.48, which is within standard range for the sector. Debt can assist ImmunoCellular Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunoCellular Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunoCellular Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunoCellular to invest in growth at high rates of return. When we think about ImmunoCellular Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Eliahu Shohet | Bolt Biotherapeutics | 56 | |
| Stefan Loren | Cellectar Biosciences | 52 | |
| Navid Malik | Northwest Biotherapeutics | ||
| Susan Bayh | Northwest Biotherapeutics | 54 | |
| Rosana Tabanelli | Bolt Biotherapeutics | N/A | |
| John Neis | Cellectar Biosciences | 60 | |
| Charles OKeeffe | Catalyst Pharmaceuticals | 78 | |
| Alton Boynton | Northwest Biotherapeutics | 78 | |
| Frederick Driscoll | Cellectar Biosciences | 67 | |
| Guillermo Eumann | Bolt Biotherapeutics | N/A | |
| Philip Coelho | Catalyst Pharmaceuticals | 74 | |
| Donald Denkhaus | Catalyst Pharmaceuticals | 72 | |
| Ron Mayron | Bolt Biotherapeutics | 51 | |
| Anibal Bernardo | Bolt Biotherapeutics | N/A | |
| Aad Winter | Pharming Group NV | 63 | |
| Iwan Harianto | Bolt Biotherapeutics | 62 | |
| Jerry Jasinowski | Northwest Biotherapeutics | 71 | |
| Guillermo Gabella | Bolt Biotherapeutics | N/A | |
| Richard Daly | Catalyst Pharmaceuticals | 57 | |
| Alfredo Gusman | Bolt Biotherapeutics | N/A | |
| Jamey Weichert | Cellectar Biosciences | 57 | |
Management Performance
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 |
ImmunoCellular Therapeutics Leadership Team
Elected by the shareholders, the ImmunoCellular Therapeutics' board of directors comprises two types of representatives: ImmunoCellular Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoCellular. The board's role is to monitor ImmunoCellular Therapeutics' management team and ensure that shareholders' interests are well served. ImmunoCellular Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoCellular Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregg Lapointe, Independent Director | ||
| Wayne CPA, CFO Treasurer | ||
| Jane Green, IR Contact Officer | ||
| Rahul Singhvi, Lead Independent Director | ||
| Mark Schlossberg, Independent Director | ||
| Anthony Lapointe, Independent Director | ||
| Gary Titus, Independent Director | ||
| Andrew Gengos, CEO and President and Director | ||
| John Yu, Chairman of the Board, Chief Scientific Officer | ||
| Anthony Gringeri, Sr. VP of Strategic Resources | ||
| David Fractor, Principal Accounting Officer, Vice President - Finance | ||
| Shalom MD, Chief CoFounder | ||
| Eli Goldberger, Chairman Founder | ||
| BS MS, Pres CEO |
ImmunoCellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImmunoCellular Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunoCellular Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunoCellular Therapeutics' short interest history, or implied volatility extrapolated from ImmunoCellular Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |